Top

Published in:

01-06-2017 | COMMENTARY

Prostate cancer incidence as an iceberg

Authors: Lorelei A. Mucci, Claire H. Pernar, Sam Peisch, Travis Gerke, Kathryn M. Wilson

Published in: European Journal of Epidemiology | Issue 6/2017

Excerpt

The epidemiology of prostate cancer is enigmatic. Globally, 1.6 million men were diagnosed with prostate cancer in 2015 [1], a notable 66% rise in its incidence from the prior 10 years. It is the most commonly diagnosed cancer in men in 103 countries, yet there is marked variation in age-adjusted incidence rates across countries and populations. A panel of epidemiologists are likely to agree only on the following risk factors as “established”: older age, African ancestry, and positive family history of prostate cancer [2]. It is the cancer with the second-highest estimated heritability [3], and genome wide association studies have now confirmed more than 180 inherited genetic risk loci in ethnically diverse populations [4, 5]. Taller height is also a probable risk factor for total prostate cancer [6]. Given the global burden of this cancer, it is alarming that there are no confirmed modifiable risk factors for prostate cancer incidence overall, which complicates our etiological understanding of the disease. …

Global Burden of Disease Cancer C, Fitzmaurice C, Allen C, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol. 2017;3(4):524–48. doi:10.1001/jamaoncol.2016.5688.CrossRef

Massimo Loda LAM, Mittelstadt ML, Van Hemelrijck M, Cotter MB (Eds) Pathology and epidemiology of cancer. Springer, Switzerland 2017.

Mucci LA, Hjelmborg JB, Harris JR, et al. Familial risk and heritability of cancer among twins in Nordic countries. JAMA. 2016;315(1):68–76. doi:10.1001/jama.2015.17703.CrossRefPubMedPubMedCentral

Eeles RA, Olama AA, Benlloch S, et al. Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nat Genet. 2013;45(4):385–91. doi:10.1038/ng.2560.CrossRefPubMed

Al Olama AA, Kote-Jarai Z, Berndt SI, et al. A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer. Nat Genet. 2014;46(10):1103–9. doi:10.1038/ng.3094.CrossRefPubMedPubMedCentral

MacInnis RJ, English DR. Body size and composition and prostate cancer risk: systematic review and meta-regression analysis. Cancer Causes Control. 2006;17(8):989–1003. doi:10.1007/s10552-006-0049-z.CrossRefPubMed

Valberg M, Grotmol T, Tretli S, et al. Prostate-specific antigen testing for prostate cancer: depleting a limited pool of susceptible individuals? Eur J Epidemiol. 2016;. doi:10.1007/s10654-016-0185-z.PubMed

Kvale R, Auvinen A, Adami HO, et al. Interpreting trends in prostate cancer incidence and mortality in the five Nordic countries. J Natl Cancer Inst. 2007;99(24):1881–7. doi:10.1093/jnci/djm249.CrossRefPubMed

Jemal A, Fedewa SA, Ma J, et al. Prostate cancer incidence and PSA testing patterns in relation to USPSTF screening recommendations. JAMA. 2015;314(19):2054–61. doi:10.1001/jama.2015.14905.CrossRefPubMed

10.

Jahn JL, Giovannucci EL, Stampfer MJ. The high prevalence of undiagnosed prostate cancer at autopsy: implications for epidemiology and treatment of prostate cancer in the Prostate-specific Antigen-era. Int J Cancer. 2015;137(12):2795–802. doi:10.1002/ijc.29408.CrossRefPubMedPubMedCentral

11.

Jemal A, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomark Prev. 2010;19(8):1893–907. doi:10.1158/1055-9965.EPI-10-0437.CrossRef

12.

Preston MA, Batista JL, Wilson KM, et al. Baseline prostate-specific antigen levels in midlife predict lethal prostate cancer. J Clin Oncol. 2016;34(23):2705–11. doi:10.1200/JCO.2016.66.7527.CrossRefPubMed

13.

Etzioni R, Penson DF, Legler JM, et al. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst. 2002;94(13):981–90.CrossRefPubMed

14.

Schwartz LM, Woloshin S, Fowler FJ Jr, Welch HG. Enthusiasm for cancer screening in the United States. JAMA. 2004;291(1):71–8. doi:10.1001/jama.291.1.71.CrossRefPubMed

15.

Ciatto S, Gervasi G, Bonardi R, et al. Determining overdiagnosis by screening with DRE/TRUS or PSA (Florence pilot studies, 1991–1994). Eur J Cancer. 2005;41(3):411–5. doi:10.1016/j.ejca.2004.09.030.CrossRefPubMed

16.

Giovannucci E, Liu Y, Platz EA, Stampfer MJ, Willett WC. Risk factors for prostate cancer incidence and progression in the health professionals follow-up study. Int J Cancer. 2007;121(7):1571–8. doi:10.1002/ijc.22788.CrossRefPubMedPubMedCentral

17.

Zu K, Mucci L, Rosner BA, et al. Dietary lycopene, angiogenesis, and prostate cancer: a prospective study in the prostate-specific antigen era. J Natl Cancer Inst. 2014;106(2):djt430. doi:10.1093/jnci/djt430.CrossRefPubMedPubMedCentral

Title: Prostate cancer incidence as an iceberg
Authors: Lorelei A. Mucci
Claire H. Pernar
Sam Peisch
Travis Gerke
Kathryn M. Wilson
Publication date: 01-06-2017
Publisher: Springer Netherlands
Published in: European Journal of Epidemiology / Issue 6/2017
Print ISSN: 0393-2990
Electronic ISSN: 1573-7284
DOI: https://doi.org/10.1007/s10654-017-0265-8

At a glance: The STEP trials

Springer Medicine

Prostate cancer incidence as an iceberg

Excerpt

At a glance: The STEP trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 6/2017

Target trial emulation: teaching epidemiology and beyond

Trends in cervical cancer incidence and mortality in Poland: is there an impact of the introduction of the organised screening?

Overdiagnostic uncertainty

Statistical science: a grammar for research

Screen-detected gallstone disease and cardiovascular disease

The value of explicitly emulating a target trial when using real world evidence: an application to colorectal cancer screening